The Week In... Pharma (06-10/04)
  • Posted on: 10/04/2020
  • Category: Industry

The Week In... Pharma (06-10/04)

COVID-19: AstraZeneca and GSK work together to boost UK testing capacity, Boehringer Ingelheim to implement its global support programme, Roche receives US government funding to step up its Acterma testing, and there’s advice on steps to strengthen UK drug supply.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk.

On the hunt for a new role, or just curious?

Visit our candidate page, or submit your CV to candidates@starmedical.co.uk!

UK coronavirus testing capacity boosted by new AstraZeneca, GSK lab

Britain will have a new coronavirus testing facility capable of carrying out 30,000 tests per day by early May, said the chief executive of pharma company AstraZeneca, helping the government meet an ambitious goal to scale up testing.

Roche takes $25M in BARDA backing to accelerate Actemra trial in COVID-19

Roche has stepped on the gas in testing Actemra for coronavirus patients, thanks to a little more help from the U.S. government.

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Boehringer Ingelheim has significantly stepped up its support to the fight against Covid-19. A Global Support Program has been set up to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.

Limiting shortages: steps for the UK to strengthen drug supply

Dr Sam Roscoe explains his recommendations for pharmaceutical companies and supermarkets in the UK to limit reliance on deliveries from overseas, to ease the impact of the COVID-19 coronavirus on drug supply chains.

Servier to acquire Danish cancer biotech Symphogen

France’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for cancer.

 

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below.